CEO message

Liber believes that nicotine vaping products should serve a therapeutic purpose, not be marketed for mass consumption.

The success of Australia’s medical model is vital because it ensures vaping is used to support smoking cessation and nicotine dependence treatment under medical supervision. This protects young people, promotes evidence-based care, and builds trust among prescribers, pharmacists, and patients.

A strong, well-regulated framework also gives responsible manufacturers the confidence to invest in safer, higher-quality products.

Australia’s model sets an important precedent by showing that vaping can be integrated into public health policy without replicating the mistakes of tobacco.

The world is watching.

Getting this right matters and Liber is focused on ensuring that, in doing so, its Nicovape® Q therapeutic vaping products maximise the number of people permanently stopping smoking using vaping technology.